Neurocrine Biosciences | GJELD



Debt Endring Dato
AbbVie USD 67.14B 3.94B 2024-12
Acadia Pharmaceuticals USD 0 0 2024-12
Agios Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 0 0 2025-03
Alnylam Pharmaceuticals USD 1.03B 945K 2025-03
Amgen USD 57.38B 2.72B 2025-03
Biogen USD 6.3B 2M 2025-03
BioMarin Pharmaceutical USD 595.65M 585K 2025-03
Cytokinetics USD 658.13M 1.01M 2025-03
Dynavax Technologies USD 260.51M 36.65M 2025-03
Exelixis USD 0 0 2025-01
Gilead Sciences USD 26.71B 3.46B 2024-12
Halozyme Therapeutics USD 1.51B 1.65M 2025-03
Incyte USD 37.12M 840K 2025-03
Ionis Pharmaceuticals USD 1.25B 5.23M 2025-03
Neurocrine Biosciences USD 0 0 2024-12
Pfizer USD 62.11B 2.24B 2025-03
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2025-03
Repligen USD 683.7M 158.13M 2025-03
Sarepta Therapeutics USD 1.14B 1.16M 2025-03
Teva Pharmaceutical Industries USD 16.65B 1.43B 2025-03
Ultragenyx Pharmaceutical USD 0 0 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Neurocrine Biosciences GJELD - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.